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Background: Barth syndrome (BS) is an X-linked infantile-onset cardioskeletal disease characterized by
cardiomyopathy, hypotonia, growth delay, neutropenia and 3-methylglutaconic aciduria. It is caused by mutations
in the TAZ gene encoding tafazzin, a protein involved in the metabolism of cardiolipin, a mitochondrial-specific
phospholipid involved in mitochondrial energy production.
Methods: Clinical, biochemical and molecular characterization of a group of six male patients suspected of having
BS. Three patients presented early with severe metabolic decompensation including respiratory distress, oxygen
desaturation and cardiomyopathy and died within the first year of life. The remaining three patients had
cardiomyopathy, hypotonia and growth delay and are still alive. Cardiomyopathy was detected during pregnancy
through a routine check-up in one patient. All patients exhibited 3-methylglutaconic aciduria and neutropenia,
when tested and five of them also had lactic acidosis.
Results: We confirmed the diagnosis of BS with sequence analysis of the TAZ gene, and found five new mutations,
c.641A>G p.His214Arg, c.284dupG (p.Thr96Aspfs*37), c.678_691del14 (p.Tyr227Trpfs*79), g.8009_16445del8437 and
g.[9777_9814del38; 9911-?_14402del] and the known nonsense mutation c.367C>T (p.Arg123Term). The two gross
rearrangements ablated TAZ exons 6 to 11 and probably originated by non-allelic homologous recombination and
by Serial Replication Slippage (SRS), respectively. The identification of the breakpoints boundaries of the gross
deletions allowed the direct detection of heterozygosity in carrier females.
Conclusions: Lactic acidosis associated with 3-methylglutaconic aciduria is highly suggestive of BS, whilst the
severity of the metabolic decompensation at disease onset should be considered for prognostic purposes. Mutation
analysis of the TAZ gene is necessary for confirming the clinical and biochemical diagnosis in probands in order to
identify heterozygous carriers and supporting prenatal diagnosis and genetic counseling.
Keywords: Barth syndrome, TAZ gene mutation, In utero cardiomyopathy, Metabolic decompensation, Lactic
acidosis, 3-methylglutaconic aciduria, Gross deletions, Metabolic cardiomyopathyBackground
The X-linked Barth syndrome (BS; OMIM #302060) is a
cardioskeletal myopathy that manifests in early infancy
with cardiomyopathy, hypotonia, growth delay, and
neutropenia [1,2]. Barth syndrome is caused by
mutations in the tafazzin (TAZ) gene on Xq28 and is
generally associated with 3-methylglutaconic aciduria
[3]. It also represents one of the neuromuscular* Correspondence: a.morrone@meyer.it
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reproduction in any medium, provided the ordisorders most frequently associated with left ventri-
cular non-compaction (LVNC) [4].
Heart failure is the main cause of death in infancy
followed by sepsis due to neutropenia [5], which causes
some variability in the clinical course of BS [6]. Until ten
years ago, mortality peaked within the first 4 years of life
but over the last decade has shifted to around puberty.
Improved survival is probably due to prompt diagnosis to-
gether with early and aggressive treatment of infections
and cardiomyopathy [7].
BS is caused by alterations to the mitochondrial metab-
olism of cardiolipin (CL), a dimeric phosphoglycerolipidd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CL is involved in the mitochondrial electron transport
chain, playing an essential role in cellular energy metab-
olism, mitochondrial dynamics and the inception of
apoptotic pathways [10-13]. Recently, CL has been
shown to be critical for the correct organization of ATP
synthase assembly [10]. CL deficiency has been detected
in several tissues and cell types from BS patients
[9,14,15] and it has been shown to affect both the
organization and morphology of the mitochondrial
inner membrane [10].
Tafazzins are phospholipid-lysophospholipid transacylases
which promote structural uniformity and molecular
symmetry among the cardiolipins [16,17]. Inhibition of
the tafazzin pathway leads to ultrastructural and func-
tional alteration of the mitochondria [16,18,19]. Studies
carried out on a BS zebrafish model suggest that the
expression of tafazzins is both tissue-specific and age-
dependent, and plays an essential role in cardiac devel-
opment and function [20]. A rat tafazzin knockdown
model exhibits hypertrophy ventricular myocytes at
birth [21]. Recently, two murine models of tafazzin
deficiency were produced by inducible short hairpin
shRNA-mediated TAZ knockdown [22,23]. Both models
showed decrease of tetralineoleyl cardiolipin and accu-
mulation of monolysocardiolipins in cardiac and skeletal
muscle, associated with mitochondrial abnormalities
and cardiac and skeletal muscle impairment, similar to
BS [22,23].
Several TAZ transcript variants encoding different
tafazzin isoforms have been described [16,24,25], but
the function of several of them is still unknown. Four
distinct tafazzin isoforms, TAZ-FL (encoding full-length
tafazzin, GenBank:NP_000107.1), TAZ-Δ5 (encoding
tafazzin lacking exon 5, GenBank:NP_851828.1), TAZ-
Δ7 (encoding tafazzin lacking exon 7, GenBank:
NP_851829.1) and TAZ-Δ5Delta;7 (encoding tafazzin
lacking exons 5 and 7, GenBank:NP_851830.1) have
been reported [26,27]. All four proteins are localized to
the mitochondria if expressed in HeLa cells [28],
but only two of them, TAZ-FL and TAZ-Δ5, have
transacylase activity [16,28] with different acyl chain
substrate specificity [16].
Mutations in the TAZ gene cause tafazzin deficiency
and sequence analysis of this gene is necessary to con-
firm the clinical and biochemical diagnosis of BS
[24,29]. The human TAZ gene contains 11 short exons
and 10 variably long introns. At present, 105 different
TAZ gene mutations have been reported [30,31], 94 of
them associated with BS [30]. However, no correlation
between the genotype and either cardiac phenotype or
disease severity has been reported in BS [32]. A database
of human TAZ gene mutations and other variants is
available on-line from the Barth Syndrome Foundation[33]. Here we report five new TAZ gene mutations in




Whole blood DNA samples from six BS patients were
examined. The heterozygous carrier status of the patients’
mothers was evaluated after informed consent was
obtained for all patients, in accordance with local ethical
committee recommendations. The clinical histories of the
patients analyzed are as follows and the pedigree charts
are shown in Figure 1:
Patient 1 (Pt1) was the first child born to non-
consanguineous parents after 36 weeks of gestation.
Weight at birth was 2.25 kg with length 47 cm. On his
first day of life, Pt1 manifested respiratory distress, lac-
tic acidosis and relative neutropenia (neutrophil count,
900/mm3). Two days later, a severe dilated cardiomyop-
athy was diagnosed by heart ultrasound. Since severe
hypotonia has also been presented, muscle biopsy was
performed and revealed clearly reduced staining for
cytochrome C oxidase, which was confirmed by a reduc-
tion in cytochome c oxidase activity measured spectro-
photometrically in muscle homogenate (44% reduction
in activity by reference to the lowest range). This child
died 10 days after birth due to heart failure. His mother
was on her second marriage. During her first marriage,
she had experienced a spontaneous abortion during her
first pregnancy whilst two sons had subsequently died
from heart failure at the ages of 2½ months and 40 days.
Suspicion of BS, and the subsequent confirmation of the
diagnosis by cardiolipin/monolysocardiolipin analysis
[16] (MLCL/CL ratio 253 on patient’s fibroblasts;
normal 0–0.3), arose only after the birth of Pt1.
Patient 2 (Pt2) was born in the 39th week of gestation,
with a spontaneous delivery after an uneventful preg-
nancy. APGAR was 1’: 8; 5’: 9; weight was 2.7 kg and
length 47 cm. After 12 h of life, the newborn exhibited
mild cyanosis with O2 Sat of 88-89%, which was moder-
ately responsive to O2 administration (O2 Sat 92-94 %),
lactic acidosis, neutropenia and dilated cardiomyopathy
with left ventricular non-compaction. Biochemical analysis
of urinary organic acids revealed 3-methylglutaconic
aciduria. This patient died at the age of one year due to
heart failure. He was the youngest of four siblings, one
healthy male, one sister and a brother who had died aged
40 days due to staphylococcal pneumonia. Autopsy of this
patient’s brother also revealed dilated cardiomyopathy.
The clinical features of Pt2 and his family history led to
suspicion of BS.
Patient 3 (Pt3) was the first child born with spontan-
eous delivery to non-consanguineous parents in the 39th
week of gestation. Dilated cardiomyopathy with increased
Figure 1 Pedigree charts of BS families.
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pregnancy as a result of a routine check-up. At birth,
APGAR was 1’: 8; 5’: 9. Further medical investigations
confirmed dilated cardiomyopathy with left ventricular
non-compaction, but the patient exhibited good cardio-
vascular compensation. However, lactic acidosis was
present and urinary organic acids analysis revealed 3-
methylglutaconic aciduria, with abnormally high levels
of pyruvic acid, 3-hydroxybutyric acid, methylglutaric
acid, 4-hydroxyphenyl lactic acid and p-hydroxyphenyl
pyruvic acid. Neutropenia was noticed, according to age
appropriate ranges, on several full blood counts over a
period of eight years. Diagnosis of BS was eventually
confirmed by molecular and biochemical analysis
(MLCL/CL ratio 70 on patient’s fibroblasts; normal 0–0.3).
Pt3 exhibits intermittent neutropenia and dilated cardio-
myopathy, but stable cardiovascular compensation. Occa-
sionally, infections have occurred with fever but have been
successfully treated with specific antibiotic therapies. To
date, the treatment with G-CSF has not been carried out
because the patient has never presented severe infections
resistant to antibiotic therapy. He is currently eight years
old, 20 kg (3rd percentile) in weight and 115.5 cm in height
(under the 2rd percentile).
Patient 4 (Pt4) was the first child of non-consanguineous
parents. Weight at birth was 2.8 kg. At the age of five
months, he had a first episode of hypotonia and heartfailure with gallop rhythm and his weight was under the
3rd percentile. Dilated cardiomyopathy was diagnosed.
Early therapeutic treatment allowed stabilization of
clinical conditions. Severe neutropenia and urinary 3-
methylglutaconic aciduria were also detected and
confirmed during subsequent evaluations. During his
life, the child has been in a good physical condition,
but neurological milestones were delayed. He is
currently eleven years old, 34.2 kg in weight (25th
percentile), 142 cm in height (25th percentile) and
exhibits dilated cardiomyopathy. BS was suspected
and then confirmed by molecular analysis during his
first physical examination, when he was 10 years old.
A second son was born when Pt4 was 5 years old.
The younger brother weighed 3.76 kg at birth and
presented with severe sepsis at 3 days. Clinical and
biochemical investigations revealed dilated cardiomy-
opathy, hypotonia, growth retardation, severe neutro-
penia and 3-methylglutaconic aciduria. At 25 months
of age, he again, suffered a severe episode of sepsis
due to pyelonephritis. The child died at the age of
two years - ten months due to heart failure.
Patient 5 (Pt5) was the first child of non-consanguineous
parents. He was born at 41 weeks of gestation, weighing
3.3 kg. APGAR was 1’: 9; 5’: 10 after a pregnancy
complicated by gestational diabetes treated with diet
therapy. Five hours after birth, he exhibited severe
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requiring intubation. Hemodynamic instability was per-
sistent with a systolic murmur of 2/6. Mild hepatomegaly
was present. Echocardiography showed non-compaction
of the left ventricular myocardium with reduced pump
function. Blood gas analysis revealed lactic acidosis. Ino-
tropic and diuretic therapy helped obtaining clinical and
hemodynamic stabilization, followed by improvement of
cardiac function. On the 8th day of life, he had a first
episode of cardiac arrest from which he was rescued by
long resuscitation but deep coma ensued. Over the
following days, clinical and hemodynamic conditions
remained critical with persistence of anuria. The child
died 12 days after birth. TAZ gene mutational analysis
confirmed the diagnosis of BS in proband and the hetero-
zygous status of the mother. A prenatal diagnosis was
performed nine months later and revealed that the foetus
in question did not have BS.
Patient 6 (Pt6) was the second child born to healthy
non-consanguineous parents. Family history includes
one healthy male first born and one natural abortion.
APGAR was 1’: 9; 5’: 10, 3.0 kg weight, 48 cm in length.
Pt6 displayed frequent regurgitation and vomiting dur-
ing the first month of life with growth delay (0.1 kg per
month). An episode of gastroenteritis with dehydration
occurred during his seventh month of life. Further clin-
ical investigations revealed dilated cardiomyopathy with
left ventricular non-compaction, alterations in ventricu-
lar repolarization, hypokinesia, gallop rhythm, mitral
and tricuspid regurgitation, and diastolic murmur 2-3/6
in the mesocardial area. Urinary 3-methylglutaconic
aciduria, neutropenia and lactic acidosis were present.
Acquired microcephaly with mild cerebral ventricular
asymmetry and hypotonia were also evident. Cardiolipin/
monolysocardiolipin analysis was performed on a dried
blood spot [16] and led to the diagnosis of BS, MLCL/CL
ratio was 7 (normal 0–0.3). As a consequence of a good
response to therapy, at the fifteenth month of life, his
physical condition was good, albeit with mild hypotrophy
of the legs. He was clinically stable until two years of age
at which time he presented with an episode of bronchitis
and otitis with fever, which was resolved with antibiotic
therapy. As in the case of Pt 3, the treatment with G-CSF
has not been carried out to date, because the patient has
never presented severe infections resistant to antibiotic
therapy. At last follow-up he was two years old, 10.43 kg
in weight (between 3rd-5th percentile) and 86.2 cm in
height (under the 3rd percentile). His clinical condition is
generally good with cardiovascular compensation and
systolic function at the lower end of the normal range.
Analysis of genomic DNA
Genomic DNA was isolated using the EZ1 DNA Blood
350 μl Kit (QIAGEN, Hilden, Germany). The entire codingregion and intron-exon boundaries of the TAZ genes of
the six enrolled patients were amplified and sequenced by
PCR using the oligonucleotides listed in Table 1. PCR
conditions are available on request. Sequencing PCR
reactions were performed using the BigDye Terminator
v1.1 Cycle Sequencing Kit (Applied Biosystems; Carlsbad,
CA, USA) and purification was carried out using Sephadex
G-50 Fine (GE Healthcare; Little Chalfont, UK). Capillary
electrophoresis was performed using ABI PRISM 3130
Genetic Analyser (Applied Biosystems) as recommended
by the manufacturer.
All nucleotide positions given in this work are based
upon the human TAZ gene nucleotide sequence
[GenBank: NG_009634.1].Multiplex PCR analysis
Multiplex PCR analysis was performed using the primer
pairs listed in Table 1. Different combinations of PCR
fragments were tested in order to confirm multi-exon
deletions in the TAZ genes of patients Pt1 and Pt2. PCR
fragment combinations Taz5 + Taz8-9, Taz5 + Taz6-7 +
Taz10-11, Taz5 + Taz10-11 and Taz1-2 + Taz10-11 were
successfully assayed. Multiplexed PCR products were
checked by agarose gel electrophoresis using 2% Agarose
Low Melting (Eurobio, France) + 1% Standard Agarose
(AB Analitica, Italy).Deletion breakpoint determination
In patients Pt1 and Pt2, who harbored large gene
deletions verified by multiplex PCR, we performed
long-range PCR (LR-PCR) using TaKaRa La Taq DNA
polymerase (TaKaRa Bio Inc, Japan) to determine the
precise locations of breakpoint boundaries. We also
performed LR-PCRs using primer TAZ 5fw (Table 1) as
the primer binding upstream of the deleted region,
coupled with a primer binding to exon 1 of the
ATP6AP1 gene located about 7000 bp downstream of
the TAZ gene. LR-PCR products were purified from a
0.8% agarose gel and sequenced by primer-walking [34].
The Clustal W program [35] was used to align
sequences located at the breakpoints.Screening for the novel missense mutation p.His214Arg
The TAZ genes of 120 male controls were analysed by
sequencing fragment Taz8-9 containing the region
encoding codon 214.Bioinformatic analysis of interspersed repeated sequences
The TAZ gene region was screened for interspersed
repeated sequences (SINEs and LINEs) and low complexity
DNA sequences using RepeatMasker [36].
Table 1 Oligonucleotides used for TAZ gene mutation analysis
Fragment name Primer Sequence 5’-3’ Included exons Amplified gene region* Length (bp)
Taz 1-2 Taz 1-2fw agtcaggggccagtgtctc 1 and 2 g.5224_5736 552
Taz 1-2rv gaaggggtttgttctgacga
Taz 3-4 Taz 3-4fw ctggggatatgggaagttgg 3 and 4 g.6642_7095 494
Taz 3-4rv ccataggtccctccaaaaca
Taz 5 Taz 5fw aaggtcatggggtaggaggt 5 g.7519_7714 236
Taz 5rv aaactcctgggcttgagtga
Taz 6-7 Taz 6-7fw ccccgagaatggttactgat 6 and 7 g.12983_13340 398
Taz 6-7rv aggcctagtctcagcacctg
Taz 8-9 Taz 8-9fw gggagctgaattgaactgga 8 and 9 g.13404_13753 390
Taz 8-9rv agacagcagacaggcagaca
Taz 10-11 Taz 10-11fw ggcactcctactgctcctca 10 and 11 g.14097_14513 457
Taz 10-11rv agcatcagtccatccctcag
*based upon the reference nucleotide sequence NG_009634.1. Positions do not include the primer sequences.
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His214Arg
Tafazzin protein sequences from 13 different species
(Macaca mulatta GenBank:NP_001028086.1, Mus muscu-
lus GenBank:NP_852657.1, Rattus norvegicus GenBank:
NP_001020919.1, Bos taurus GenBank:DAA13200.1, Ory-
ctolagus cuniculus GenBank:NP_001164847.1, Rhinolo-
phus ferrumequinum GenBank:ACC68906.1, Salmo salar
GenBank:ACN11123.1, Danio rerio GenBank:NP_0010-
01814.1, Ictalurus punctatus GenBank:NP_001187914.1,
Aedes aegypti GenBank:XP_001653587.1, Drosophila me-
lanogaster GenBank:NP_477432.3, Ascaris suum Gen-
Bank:ADY45663.1, Schistosoma japonicum GenBank:
CAX73490.1) were aligned with the human TAZ sequence
(GenBank:NP_000107.1) using the Clustal W program
[35]; multialignments were checked to determine the
degree of evolutionary conservation of the amino acid
residue (His214) involved. Further, the His214Arg
amino acid substitution was also analysed by
PolyPhen [37], which makes a prediction as to
whether an amino acid change is likely to be deleteri-
ous to protein function [38]. Profile scores of >2.0 in-
dicate that the polymorphism is probably damaging
to protein function whereas scores of 1.5–2.0 are
possibly damaging, and scores of <1.5 are indicative
of a benign variant. To confirm results from
PolyPhen, we used (i) the MutPred Server [39], which
generates a probability for a given mutation to be
deleterious to protein function (scores that range
from 0 to 1), and the likelihood of it being patho-
genic (scores over 0.5) [40] and (ii) SIFT [41], which
yields a score of ≤0.05 if the amino acid substitution
is predicted to be damaging and >0.05 if it is
predicted to be tolerated.Results
Identification of the TAZ mutations in six new unrelated
BS patients
Molecular analysis of the TAZ gene in the six patients
confirmed the clinical diagnosis by revealing that each one
of them carried a mutated TAZ allele. Six different TAZ
mutations were identified, including the previously
reported c.367C>T (p.Arg123Term) nonsense mutation
[42] and five new mutations: a c.641A>G (p.His214Arg)
missense variant, the c.284dupG (p.Thr96Aspfs*37)
microinsertion, the c.678_691del14 (p.Tyr227Trpfs*79)
microdeletion and the two g.8009_16445del8437 and g.
[9777_9814del38; 9911-?_14402del] large rearrangements.
The TAZ gene variants identified in the BS patients and
their related clinical features are summarized in Table 2.
Confirmation of the likely pathogenicity of p.His214Arg
The p.His214Arg amino acid substitution was not found
in 120 TAZ alleles from healthy male controls.
ClustalW analysis revealed a very high degree of evolu-
tionary conservation of histidine at position 214 (His214) in
the tafazzin protein (Figure 2). Not only do all vertebrate
tafazzins contain histidine at the analogous location but
also do the tafazzins of two insects (Aedes aegypti and
Drosophila melanogaster) and a flatworm (Schistosoma
japonicum). This implies that this histidine residue must
have been conserved for the last ~700 Ma, since prior to
the divergence of deuterostomes from protostomes. Such a
degree of evolutionary conservation implies a key function
for this residue.
PolyPhen predicted that this mutation is probably dam-
aging with a score of 2.862 for TAZ-FL (GenBank:
NP_000107.1) and 3.123 for the TAZ-Δ5 isoform
(GenBank:NP_851828.1, [25]). This prediction was
Table 2 Genotypic and phenotypic data for the BS patients under study
Patient TAZ gene mutation Reference Age of onset Manifestations at onset Exitus




this work twelve hours of
life




Pt3 c.641A>G (p.His214Arg) this work in utero dilated cardiomyopathy living, 8 years old
Pt4 c.367C>T (p.Arg123Term) [42] five months hypotonia and heart failure living, 11 years old
Pt5 c.678_691del14 (p.
Tyr227Trpfs*79)




Pt6 c.284dupG (p.Thr96Aspfs*37) this work first month frequent regurgitation and vomiting, growth delay,
lactic acidosis
living, 3 years old
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score g = 0.677) and SIFT (score of 0.01 for TAZ-FL; 0.02
for TAZ-Δ5).
Interspersed repeated sequences in the TAZ gene
Results obtained from the analysis of the human TAZ gene
sequence (GenBank:NG_009634.1) with RepeatMasker are
summarized in Table 3.
Characterization of the large deletion breakpoints
In patients 1 and 2, PCR analysis of the TAZ gene exonic
sequence could not amplify exons 6 to 11. Multiplex PCR
analysis was then performed, which resulted in the ampli-
fication of exons 1 to 5 but not exons 6 to 11, indicating
that gross deletions spanned a large region of the TAZ
gene in both patients. LR-PCR, performed to determine
deletion breakpoints, yielded amplicons that were shorter
in length than the PCR products obtained from healthy
controls. Characterization of the breakpoint junctions by
sequencing analysis in Pt1 revealed the deletion of an
8437 bp genomic fragment (g.8009_16445del8437) span-
ning exons 6 to 11 of the TAZ gene inclusive. The break-
point junctions mapped to within two AluY repeats which
were in the same orientation and located respectively
0.357 kb downstream of the exon 5 donor splice site, andFigure 2 Multialignment of the amino acid sequence of tafazzin whic
patient Pt3. Gray squares indicate amino acid residues with 100% of hom
indicated by a square.1.979 kb downstream of the exon 11 donor splice site
(Figure 3A). The g.8009_16445del8437 deletion gave rise
to a new hybrid AluY element containing the breakpoint
(Figure 3A).
The analysis of the breakpoint junctions in Pt2 revealed
the g.[9777_9814del38; 9911-?_14402del] complex allele.
A deletion of 38 bp between nucleotides 9777 and 9814
was accompanied by a larger deletion of more than 4 kb
(Figure 3B). The upstream breakpoint junction of the
larger deletion is located around 2246–2260 bp down-
stream of the exon 5 donor splice site (nucleotides
9898_9911 in GenBank:NG_009634.1), within an A-rich
sequence (14 A in the Ref Seq). One characteristic of our
sequencing method was that, after a repeat structure such
as a polyA stretch of >9-10 nucleotides, the sequencing
signal became unreadable making it impossible to deter-
mine the number of As in the repeated sequence. Hence
we could not determine precisely at which nucleotide,
between 9898_9911 in NG_009634.1, the upstream break-
point of Pt2 occurred. However, the downstream junction
was located within exon 11 (nucleotide c.814).
Determination of heterozygous carrier status
Since the TAZ allele of Pt2 harbors a portion of exon
11, we were able to amplify across his deletion junctionsh surrounds the new p.His214Arg substitution identified in BS
ology between the sequences analyzed. The His214 residue is
Table 3 Interspersed repeat sequences within the TAZ










- SINEs: 27 6487 37.74
ALUs 25 6143 35.74
MIRs 2 344 2.00
- LINEs: 6 1197 6.96
* TAZ gene reference sequence NG_009634.1.
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obtaining a fragment of almost 2.6 kb. The same PCR
reaction yielded a fragment of around 7 kb from the
wild-type TAZ allele. Such LR-PCR amplification was
extended to female relatives of Pt2, which allowed con-
firmation of the heterozygous carrier status of both his
mother and sister (Figure 4).
The mother of Pt1 declined further investigation.Discussion
Mutations underlying human inherited disease vary
greatly in size, from gross rearrangements to single base-
pair substitutions. They can also originate via a number of
different molecular mechanisms. Irrespective of the type
of lesion, the nature, location and frequency of human
gene mutations are shaped to a considerable extent, andFigure 3 Schematic representation of the TAZ deletions involving exo
exon 5 donor splice site and downstream of the exon 11 donor splice site
causing the g.8009_16445del8437 mutation identified in Pt1. B) Relative loc
Pt2 (one 38 bp deletion and one >4 kb deletion). Microhomologies that co
g.[9777_9814del38; 9911-?_14402del] are indicated.often in remarkably predictable ways, by the local DNA
sequence environment (for a review, see [43]).
Almost 45% of the genomic sequence of the human
TAZ gene is represented by interspersed repeated
sequences (SINES and LINES) and 76% of these (35% of
the TAZ gene sequence) are Alu sequences. The propor-
tion of the whole human genome that is Alu sequence is
estimated to be around 10.6% [44]. A high proportion of
Alu repeats within a gene sequence can promote gross
gene rearrangements [45], as reported for example for the
PAFAH1B1 (LIS1) gene [46]. We report here an intragenic
deletion in the TAZ gene, which appears to have been
mediated by recombination between two AluY repeats.
The deletion junctions in Pt1 were located within the two
highly homologous and similarly oriented AluY repeats
(Figure 3A). Non-allelic homologous recombination
(NAHR) between Alu elements is a likely mechanism of
mutation in this patient [45]. An Alu-mediated TAZ gene
deletion that ablates the entire gene has also been
reported [47]. These data suggest that the TAZ gene is
located within a genomic environment that is particularly
rich in repeats that can promote genetic rearrangements.
HGMD Professional v.2012.2 ([30] update 29th June
2012) reports a total of 104 TAZ gene mutations of which
35.6% are missense, 12.5% are nonsense, 18.3% affect spli-
cing, 19.2% are microdeletions, 7.7% are microinsertions
and 6.7% are large gene rearrangements. Of the eight
gross gene rearrangements reported, three were published
[31,47,48] whereas the remaining five can be retrievedns 6–11. A) Relative location of AluY repeats downstream of the
which are postulated to have been involved in the NAHR event
ations of the breakpoint junctions of the deleted regions identified in
uld have primed the sequential slippage events at the origin of
Figure 4 Agarose gel analysis of the heterozygous carriers of
the g.[9777_9814del38; 9911-?_14402del]. M) Marker; 1) Mother
of Pt2; 2) Sister of Pt2; 3) Pt2; 4) Normal control; 5) no template DNA.
Fragment of ~2.6 kb corresponds to the g.[9777_9814del38;
9911-?_14402del] allele.
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Database” [33] to which they were submitted directly,
without supporting details. One mutation in the latter
group is reported to involve the deletion of exons 6–11. In
our patient sample, we identified deletions of exons 6–11
in two patients (Pt1 and Pt2) who harbored two different
genetic rearrangements. Defining the exact breakpoints of
such rearrangements is a prerequisite to identify heterozy-
gous carriers of TAZ gene rearrangements, and for pre-
natal diagnosis.
Despite the high density of Alu repeats in the TAZ gene,
the deletion observed in Pt2 was not mediated by NAHR
between Alu elements. In this patient, the genetic
rearrangement was found to be more complex than in Pt1
(one 38 bp deletion and one >4 kb deletion) and might
have been prompted by and Serial Replication Slippage
(SRS) [49]. Consistently with this assertion, the sequences
flanking the breakpoints exhibit microhomologies as
depicted in Figure 3B. Sequential slippage events at the
3’ end of the nascent strand during DNA replication
could have been primed by these microhomologies [49].
We postulate that the SRS model, instead of the more
recently proposed FoSTeS model [50], is the more likely
mechanism of the rearrangement in Pt2 since the SRS
model assumes that the replication slippage occurs at
closely adjacent sites and gives rise to relatively small
rearrangements (up to 10 kb), whereas the FoSTeS
model is better suited to explain template switching that
occurs over long distances, generating much larger
DNA rearrangements (120 to 550 kb) [49]. Whatever
the underlying mechanism, characterization of gross
rearrangements in the TAZ gene is essential foridentifying heterozygous carriers among female relatives
of the probands and, as it is the case for Pt2, to confirm
the carrier status of close female relatives.
In addition to these gross gene rearrangements, we
identified two frameshift variants in the TAZ genes of our
patients: a small 14 bp deletion (Pt5) and a small duplica-
tion (Pt6). Ball et al. [51] suggested that a combination of
slipped mispairing mediated by direct repeats and second-
ary structure formation promoted by symmetric elements
could account for most microdeletions and microinsertions.
We analyzed the sequence environment as suggested [51],
considering the 10 bp of DNA sequence flanking the
c.678_691del14 deletion detected in Pt5 (ACAGTCCGCCct
acttcccccgctTTGGACAGGT). This region is G/C rich and
the deletion is flanked by CCGC repeats, consistently with
a slipped mispairing model. At the protein level, the
c.678_691del14 deletion is predicted to lead to a p.
Tyr227Trpfs*79 frameshift.
The c.284dupG duplication in Pt6 (GTTGATGC
GTTGgGTGAGGAGGA) might be explained by the
modified slipped mispairing model [52], whereby
misalignment occurs between a specific contiguous
sequence on one strand and a second partially homolo-
gous, yet interrupted, sequence on the other strand. One
repeat copy only becomes capable of base-pairing once
an additional base has been inserted or deleted. In the
case of Pt6, the first repeat is GTTGA whilst the second
repeat is GTTGGA; slipped mispairing would therefore
account for the duplication of a G in this first repeat. At
the protein level, the c.284dupG mutation is predicted
to lead to a frameshift p.Thr96Aspfs*37 with premature
termination of translation.
We also detected two single nucleotide substitutions in
the TAZ genes: c.641A>G (Pt3) and c.367C>T (Pt4).
c.641A>G leads to the substitution p.His214Arg, which,
although not predicted to change the polarity of the
involved residue, occurs in a residue which is evolutionar-
ily conserved, suggesting an essential role in protein func-
tion. We are unable to infer about the possible impact of
the missense change directly on the three-dimensional
structure of human tafazzin, as the crystal structure is not
available, however molecular characterization of mutant
TAZ alleles has been performed in a Saccharomyces
cerevisiae model of Barth syndrome [53]. While the
corresponding residue in the S. cerevisiae Taz1p ortholog
is not conserved (it is an Alanine), the p.His214Arg mu-
tation occurs in a putative unusual membrane anchor
region in yeast Taz1p [53]. Interestingly, mutations in this
membrane anchor result in two distinct biochemical fates:
low fidelity sorting with increased rates of aggregation and
aberrant macromolecular assembly [53].
Pt4 carried the p.Arg123Term nonsense mutation previ-
ously reported by van Werkhoven et al. [42]. According
to the Human Tafazzin Gene Mutation and Variation
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mutation have been reported, suggesting recurrent
mutation at this CpG dinucleotide mutation hotspot.
We found lactic acidosis to be present in 5/6 patients
at the time they were brought to clinical attention,
suggesting that, in addition to 3-methylglutaconic
aciduria and neutropenia, lactic acidosis is an important
biochemical marker for suspecting BS. In addition, a
deep metabolic decompensation during the first hours
of life, including respiratory distress and cyanosis with
oxygen desaturation, was associated with the most
severe outcome (Pt1, P2 and Pt5). Deep metabolic de-
compensation associated to these other signs may thus
correlate with the severity of the disease more than it
does the time of onset of cardiomyopathy that, for
instance, was already detected in utero in Pt3 who was
still alive at last follow up [54,55]. The alteration of
cardiolipin metabolism in BS leads to an abnormal lipid
structure of the inner mitochondrial membrane. This may
result in mitochondrial leakage of metabolites, such as the
lactate as we observed in our BS patients. Thus, we could
hypothesize that an acute metabolic decompensation
during the first hours of life, associated with respiratory
distress and oxygen desaturation, or with other signs such
as mild hyperammonaemia, hypoglycaemia and elevated
transaminases [54] could be correlated to a deeper impair-
ment of the mitochondrial function at the onset of BS and
thus to an earlier and deeper cardioskeletal tissue damage.
However, it cannot be excluded that the severity of the
metabolic decompensation can be related also to other
still undefined factors, as it has been reported that the
pathophysiology of Barth syndrome can unlikely be
explained solely on the basis of cardiolipin abnormalities
and additional factors could play a role in modifying the
disease expression [56]. Anyhow, these assertions remains
to be proven.
Several cases of clinical manifestations of BS being
detected in utero, as in the case of Pt3, have been
reported [57,58]. Therefore, cardiolipin analysis or mu-
tational analysis of the TAZ gene should be considered
in cases of heart failure or sepsis during the neonatal
period or of in utero cardiomyopathy. Such analysis
should also be considered when investigating the causes
of natural abortions (e.g. Pt1 and Pt6) as also previously
reported [58].
Early diagnosis of BS is a prerequisite for early and
effective therapy and follow-up, and for preventing crisis
due to sepsis, as suggested by the clinical histories of Pt3
and Pt6. Moreover, prompt molecular characterization of
BS patients is vital for prenatal diagnosis and for
preventing the recurrence of BS in the same family (e.g.
Pt5). Late diagnosis of BS can lead to familial recurrence
of the disease as observed in the families of Pt1, Pt2 and
Pt4.Conclusions
The human TAZ gene sequence is rich in interspersed
repeats that may promote the occurrence of gross
gene rearrangements albeit with different mutational
mechanisms. Therefore, gross TAZ rearrangements,
which may appear to be similar in different patients on
the basis of ablated exons, may actually represent
private mutations.
Lactic acidosis is an early biochemical marker of BS,
together with 3-methylglutaconic aciduria, such as are
metabolic decompensation, cardiomyopathy, heart failure
and hypotonia. The severity of the metabolic decompensa-
tion at onset of BS correlates with the severity of the
clinical course of the disease, and is therefore important
for prognostic assessment. Cardiomyopathy may be
detectable in utero, but its time of onset does not seem
to be necessarily correlated with the severity of the
prognosis.
Mutational analysis of the TAZ gene is necessary to
confirm the clinical and biochemical diagnosis in
probands, to identify heterozygous carriers and for
prenatal diagnosis, but should also be considered in the
presence of cardiomyopathy in utero and of natural
abortion together with cardiolipin ratio analysis.
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